Torrent Pharmaceuticals Ltd AI Stock Analysis
Want to see IN:TORNTPHARM full AI Analyst Report?
Torrent Pharmaceuticals Ltd (TORNTPHARM) AI Stock Analysis
Torrent Pharmaceuticals Ltd
(NSE:TORNTPHARM)
The overall score of 62 reflects a company with strong fundamental business momentum and a positive strategic outlook, as highlighted by robust revenue growth and successful integration progress. However, this is significantly weighed down by poor technical momentum, with the stock in a clear downtrend, and a very expensive valuation (P/E of 70.67) that leaves little room for error. The financial performance is solid but shows some strain on gross margins, making the current price level difficult to justify despite the optimistic long-term narrative from management.
Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.78T
- Dividend Yield
- 0.32%
- Average Volume (3M)
- 23.21K
- Price to Earnings (P/E)
- 76.9
- Beta (1Y)
- 0.43
- Revenue Growth
- 42.06%
- EPS Growth
- -3.48%
- Country
- India
- Employees
- 20,341
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Torrent Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key...
How the Company Makes Money
Torrent Pharmaceuticals primarily makes money by selling finished-dose pharmaceutical formulations (branded generics) to healthcare channels (pharmacies, hospitals, and distributors) in India and abroad. In its core India business, revenue is driven...
Torrent Pharmaceuticals Ltd Earnings Call Summary
The call was predominantly positive, supported by 51% consolidated revenue growth, 54% operating EBITDA growth, strong Torrent India, Curatio, Brazil, U.S., and semaglutide performance, and integration synergies tracking ahead of plan. The main challenges were JB integration-related disruption, Germany's decline, semaglutide supply-driven share loss, expected U.S. price pressure, and Brazil's approval and competitive environment.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects JB India branded business growth in H2 to be higher than double digit and total JB business growth to recover to double digit in H2, with recovery gradually quarter-on-quarter; cost synergies remain at INR 450 crores, with most potentially coming through by the next year and achieved in two years' time instead of three years, while revenue synergies should start gradually coming through next year, with initiatives taking 6-12 months and international opportunities 2-3 years. JB EBITDA margins should continue gradual improvement for the next two, three quarters, while H2 EBITDA margin should be little higher than 33.5%; R&D spend may remain elevated for 2-3 years, with U.S. filings increasing from very low single digits to maybe high single digits and spend expected between 4%-4.5% even in the following year. India field force could potentially expand by 500 MRs or so to something between 9,500-9,600, Brazil should continue to grow double-digit, mid-teens or in that range and at least superior to 10%, closer to 15% growth in the coming years, Germany could see a slight decline in the coming quarters followed by stability after maybe three or four quarters, ROW growth can conservatively be taken at 6%-9%, Brazil semaglutide may launch in the next 6-9 months, Curatio should sustain high growth for at least a couple of years, and generic semaglutide could reach INR 800 crores for the first year and INR 2,000-INR 2,500 in 3-5 years.
Torrent Pharmaceuticals Ltd Financial Statement Overview
Summary
Strong revenue growth (+16.1%) and healthy net margins (15.5%) are offset by a sharp decline in gross margin (48.8% vs. ~75% historically). The balance sheet is conservative (D/E 0.40) with robust ROE (25.8%), though recent asset expansion introduces integration risk. Positive operating cash flow (INR 26.3B) and solid FCF conversion (0.74x) support financial health, but uneven cash flow growth and moderate debt coverage (0.32x) temper the score.
Income Statement
68PositiveBalance Sheet
82Very PositiveCash Flow
71Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 173.48B | 139.80B | 113.17B | 105.62B | 94.64B | 84.19B |
| Gross Profit | 88.61B | 68.24B | 84.33B | 77.75B | 66.36B | 58.81B |
| EBITDA | 56.49B | 32.57B | 37.19B | 35.00B | 28.81B | 21.41B |
| Net Income | 21.24B | 21.63B | 19.11B | 16.56B | 12.45B | 7.77B |
Balance Sheet | ||||||
| Total Assets | 446.15B | 443.12B | 149.90B | 150.61B | 150.12B | 131.00B |
| Cash, Cash Equivalents and Short-Term Investments | 29.86B | 23.70B | 6.91B | 10.04B | 7.23B | 5.83B |
| Total Debt | 141.07B | 150.25B | 32.02B | 40.22B | 53.68B | 40.70B |
| Total Liabilities | 262.42B | 267.27B | 73.99B | 82.04B | 88.14B | 71.47B |
| Stockholders Equity | 183.73B | 83.89B | 75.91B | 68.56B | 61.98B | 59.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 19.55B | 19.74B | 28.33B | 17.94B | 16.00B |
| Operating Cash Flow | 0 | 26.32B | 25.85B | 32.66B | 23.68B | 18.03B |
| Investing Cash Flow | 0 | -127.49B | -5.40B | -1.68B | -24.15B | -1.97B |
| Financing Cash Flow | 0 | 105.78B | -22.98B | -27.80B | 770.00M | -17.81B |
Torrent Pharmaceuticals Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Neutral. The current price of 4689.95 is above the 20-day moving average (MA) of 4634.16, below the 50-day MA of 4756.82, and above the 200-day MA of 4539.14, indicating a neutral trend. The MACD of -1.81 indicates Negative momentum. The RSI at 49.94 is Neutral, neither overbought nor oversold. The STOCH value of 46.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TORNTPHARM.
Torrent Pharmaceuticals Ltd Peers Comparison
Overall Rating
IN:ZYDUSLIFE70Outperform
IN:LUPIN67Neutral
IN:MANKIND67Neutral
IN:SUNPHARMA64Neutral
IN:DRREDDY63Neutral
IN:TORNTPHARM62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | INR 1.19T | 28.63 | ― | 0.08% | 24.02% | -14.86% | |
| 67Neutral | INR 902.01B | 17.35 | ― | 0.91% | 24.22% | 20.24% | |
| 67Neutral | INR 1.08T | 48.34 | ― | 0.04% | 13.27% | 27.32% | |
| 64Neutral | INR 4.48T | 40.86 | ― | 0.86% | 12.13% | 4.94% | |
| 63Neutral | INR 1.15T | 41.01 | ― | 0.58% | -3.60% | -52.23% | |
| 62Neutral | INR 1.78T | 76.85 | ― | 0.32% | 42.06% | -3.48% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:TORNTPHARM | Torrent Pharmaceuticals Ltd | 4689.95 | 930.10 | 24.74% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1380.00 | 144.29 | 11.68% | |
| IN:LUPIN | Lupin Limited | 1972.50 | -59.91 | -2.95% | |
| IN:MANKIND | Mankind Pharma Ltd. | 2625.00 | 400.95 | 18.03% | |
| IN:SUNPHARMA | Sun Pharmaceutical Industries Limited | 1866.95 | 123.18 | 7.06% | |
| IN:ZYDUSLIFE | Zydus Lifesciences Limited | 1189.00 | 261.58 | 28.21% |
Torrent Pharmaceuticals Ltd Corporate Events
Torrent Pharmaceuticals completes electronic dispatch of postal ballot notice
Torrent Pharmaceuticals Ltd has completed the electronic dispatch of its Postal Ballot Notice to shareholders whose email IDs were registered as of July 31, 2026, in line with the Companies Act, 2013 and SEBI Listing Regulations. The company also pub...
Torrent Pharma Announces Completion of Independent Director’s Term
Torrent Pharmaceuticals Ltd., a publicly listed Indian pharmaceutical manufacturer and marketer, operates under SEBI’s regulatory framework on both BSE and NSE, serving healthcare markets while maintaining compliance-focused governance structures. It...
Torrent Pharma posts Q1 FY27 earnings call recording online
Torrent Pharmaceuticals Ltd has uploaded the audio recording of its conference call with analysts and investors discussing financial results for the quarter ended June 30, 2026, to the company’s website, in line with SEBI disclosure regulations. The...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
